Stage IIIB Breast Cancer Completed Phase 2 Trials for Tipifarnib (DB04960)

IndicationStatusPhase
DBCOND0028549 (Stage IIIB Breast Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00082810Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast CancerTreatment
NCT00049114Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast CancerTreatment